INTS vs JAZZ
Intensity Therapeutics, Inc. Common stock (INTS) versus Jazz Pharmaceuticals PLC (JAZZ) — a side-by-side from cached financials, not a winner call.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
INTS does not have a complete income-statement cache yet.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
INTS currently screens at market cap $7.7M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Not investment advice. Open the INTS and JAZZ stock pages for the full models.
Not investment advice.